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Objectives. To investigate the in vitro effects of Sodium Tetradecyl Sulphate (STS) and Polidocanol (POL) on clotting
tests, clotting factors, platelets and microparticles.
Materials and methods. Platelet rich (PRP) and platelet poor (PPP) plasmas were incubated with varying concentra-
tions of STS and POL. Clotting tests, platelet/plasma turbidity, and microparticle studies were performed. Specimens
were mixed with individual factor deficient plasmas and clotting factor activities were studied.
Results. STS at high concentrations (>0.3%) destroyed platelets, microparticles and the clotting factors V, VII and X. It
prolonged all clotting tests including prothrombin time (PT), activated partial thromboplastin time (APTT), non-activated
partial thromboplastin time (NAPTT), thrombin time (TT), factor Xa clotting time (XACT) and surface activated clotting
time (SACT). Higher concentrations of POL were required to achieve some anticoagulant activity. Low sclerosant concen-
trations shortened XACT and SACT, and induced release of procoagulant platelet derived microparticles. Increased expo-
sure time resulted in increased procoagulant activity. STS at concentrations higher than 0.5% precipitated a complex
containing apolipoprotein b and fibrinogen.
Conclusions. Detergent sclerosants affect the clotting mechanism by interfering with clotting factor activities, procoagu-
lant phospholipids and platelet derived microparticles. STS has more anticoagulant activity than POL in high concentra-
tions. Low concentration sclerosants demonstrate procoagulant activity.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Keywords: Varicose veins; Sclerotherapy; Sclerosing solutions; Blood coagulation; Phospholipids; Detergents.
Eur J Vasc Endovasc Surg 34, 731e740 (2007)
doi:10.1016/j.ejvs.2007.07.011, available online at http://www.sciencedirect.com onIntroduction
One traditional approach to the treatment of varicose
veins has been the surgical removal of these vessels.
The modern alternative is to occlude incompetent
vessels by endovenous laser ablation or ultrasound
guided sclerotherapy (UGS). UGS was first introduced
in 1989 to treat truncal superficial veins, tributary
veins, and incompetent perforators.1,2 Ultrasound
guidance has significantly enhanced the safety and
effectiveness of sclerotherapy by providing accurate
visualisation of the target vessels, monitoring the
effectiveness of the sclerosing agent and ultimately
assessing the success or failure of the treatment.3
Modern sclerotherapy is performed using deter-
gent sclerosants such as Sodium Tetradecyl Sulphate
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nism of sclerotherapy is destruction of the endothelial
lining of the target vessel, exposure of the basal layer
collagen, induction of vasospasm and ultimately com-
plete vessel fibrosis. With ultrasound monitoring,
sclerosants have been observed to enter the deep
venous system via the perforators or junctions, but
the clinical incidence of post-sclerotherapy deep
vein thrombosis or pulmonary embolism remains
very low.4e6
Sclerosants have been reported to have no effect on
the coagulation system in some publications7,8 whilst
others have reported minor changes in vivo.9e14 Fegan
noted that apart from a minor increase in the platelet
count of some patients, STS had no effect on clotting
times.15 Others have reported the lytic effects of scle-
rosants on platelets and other cells and concluded that
ADP release could stimulate platelet aggregation.16,17
Given the low incidence of post-sclerotherapy
thromboembolic complications, we aimed to investi-
gate the anti-thrombotic potential of these agentsar Surgery. Published by Elsevier Ltd. All rights reserved.
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nism. In particular, we investigated the effects of these




Blood was collected from normal healthy volunteers
following informed consent by clean venipuncture
into one ninth its volume of 0.109 M trisodium citrate
solution in plastic tubes. Platelet rich plasma (PRP)
was harvested after centrifuging for 10 minutes at
150 g. Platelet poor plasma (PPP) was obtained by
centrifugation for 20 minutes at 2,000 g. Samples
were incubated with increasing sclerosant concentra-
tions for 30 minutes at 20 C.
Sclerosants
Sodium Tetradecyl Sulphate (STS) was obtained as
FIBRO-VEIN 3% (Australian Medical & Scientific,
Artarmon, NSW, Australia) and Polidocanol (POL)
was obtained as AETHOXYSKLEROL 3% (Chemische
Fabrik Kreussler & Co GmbH, Wiesbaden, Germany).
These agents were slowly added to plasmas in plastic
tubes or microwells using syringes or variable volume
pipettors. Low concentrations of sclerosants used in
this study are typical of those most commonly used
in clinical practice to treat small vessels. We initially
used much wider concentration ranges for the sclero-
sants but later only reported on the levels at which
changes in clotting tests happened.
Clotting tests
Clotting tests were carried out on an ACL300 (IL/
Beckman/Coulter, Milan, Italy) and a ST4 semi-auto-
mated machine (Diagnostica Stago, Asnieres, France).
Platelet counts were determined with a Cell Dyn 4000
instrument (Abbott Diagnostics Division, Santa Clara,
CA, USA).
Thrombin time (TT) tests were carried out by mix-
ing 0.10 ml prewarmed plasma samples with 0.10 ml
bovine thrombin (Dade-Behring, Marburg, Germany)
at 2.5 NIH u/ml and timing to a clotting endpoint.
Prothrombin time (PT) tests were carried out using
0.05 ml test plasmas and 0.10 ml Thromborel S (Dade
Behring, Marburg, Germany) in the ACL300.
Activated partial thromboplastin time (APTT) tests
were carried out using 0.05 ml plasma samples pre-
incubated with 0.05 ml of various APTT reagents for
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after the addition of 0.05 ml 0.025 M calcium chloride.
Factor Xa activated clotting time (XACT) tests were
carried out as previously described.18 0.05 ml plasma
samples were mixed with 0.10 ml prewarmed XACT
reagent (Haematex Research, Hornsby, Australia)
and the time to a clotting endpoint at 37 C was deter-
mined. In some cases the test samples were mixed 1:1
with a phospholipid deficient animal plasma to make
the system more specific for procoagulant phospho-
lipid. We have previously described the sensitivity
of the XACT test for procoagulant phospholipid.19
Non-activated partial thromboplastin time
(NAPTT) tests were carried out by prewarming
0.05 ml plasma samples for 2 minutes, then adding
0.1 ml of a 1:1 mix of procoagulant phospholipid re-
agent (Haematex Research) and 0.025 M calcium chlo-
ride and timing to a clotting endpoint at 37 C. The
NAPTT assay19,20 is based upon a modification of
the APTT test. Procoagulant phospholipids are re-
tained in the test reagent, but contact activators are re-
moved to allow the assay to be dependent upon
contact activation.
Surface activated clotting time (SACT) is an APTT
with contact activator but without phospholipid.
The test method is very similar to the silica clotting
time21 and the kaolin clotting time22 in that phospho-
lipid is rate limiting. These tests are extremely sensi-
tive to procoagulant phospholipid, usually derived
from activated platelets. Thus SACT shortening is sen-
sitive to procoagulant phospholipid. SACT tests were
carried out by preincubating 0.05 ml plasma samples
with 0.05 ml of a silicate-based contact factor activat-
ing reagent (SACT reagent, Haematex Research) at
37 C for 5 minutes and then timing to a clotting end-
point after the addition of 0.05 ml of 0.025 M calcium
chloride.
Clotting times were performed for a maximum of
60 seconds for TT, 120 seconds for PT, 300 seconds
for APTT, 360 seconds for NAPTT, 240 seconds for
SACT and 120 seconds for XACT.
A summary of the tests used and their specificities
is shown in Table 1.
Clotting factor assays
Coagulation factor assays were carried out using stan-
dard one stage automated procedures on the ACL300.
Thus test specimens were diluted 1/5, mixed with
individual factor deficient plasmas and then tested
by PT test for extrinsic factors and by APTT test for
intrinsic factors. PT and APTT results were interpolated
onto calibration plots generated with 1/5, 1/10, 1/20
733Sclerosants and Coagulationand 1/40 dilutions of pooled normal plasma. The PT re-
agent used was Thromborel S (Dade-Behring) and the
APTT reagent was Intrinsin LR (Haematex Research).
Individual factor deficient plasmas were obtained
from Dade Behring (Marburg, Germany).
Microparticle analysis
Flow cytometry antibodies, Annexin V and TRU-
Count tubes were obtained from Becton Dickinson
(USA). Microparticle counts were performed by add-
ing 0.05 mL of test sample to 0.2 mL of 0.02 M HEPES
pH 7.0 buffered 0.15 M sodium chloride solution.
0.01 mL of this mixture was added to antibody
(CD41a-PerCP-Cy5.5), Annexin V-APC and HEPES
buffered saline solution containing 2.5 mM CaCl2.
Control tubes contained 2.5 mMK2EDTA. This was
incubated for 30 minutes before the addition of
1 mL HEPES buffer containing 2.5 mM CaCl2. Count-
ing was performed relative to beads in TRU-Count
tubes (Becton-Dickinson). Platelet-derived microparti-
cles were defined as events less than 1.09 mm in diam-
eter that bound Annexin V and CD41a-PerCP-Cy5.5.
Turbidity studies
Sample turbidity was measured in 0.2 ml volumes of
plasma and sclerosant mixtures in 96 well flat-
bottomed microplates. A Titertek Multiskan micro-
plate reader (Thermo Lab Systems, Finland) was
used with a 415 nm filter.
Protein analysis
This service was provided by the Australian Proteo-
mic Analysis Facility (APAF) at Macquarie University
(North Ryde). Proteins were digested with trypsin,
peptides separated by high pressure liquid chroma-
tography and then subjected to mass spectrometry
Table 1. Specificity of the clotting tests used for various clotting
factors and procoagulants
Clotting Test Mainly dependent on
Thrombin Time (TT) Fibrinogen and antithrombin
Prothrombin Time (PT) Fibrinogen and factors VII, X, V, II
Activated Partial
Thromboplastin Time (APTT)
Fibrinogen and factors XII, XI,









Factor Xa Activated Clotting
Time (XACT)
Procoagulant phospholipid,
factors V and II.using matrix assisted laser desorption ionisation
(MALDI). Results were derived after computer analy-
sis using standard libraries of known peptide
fragments.
Results
Effect of STS and POL on clotting tests
Clotting tests were performed in PPP (Fig. 1) and PRP
(Fig. 2) following incubation with varying concentra-
tions of sclerosants for 30 minutes.
High concentrations of both sclerosants prolonged
PT, APTT, NAPTT, XACT and SACT in both PPP
and PRP. TT results were prolonged by increasing
concentrations of STS, but not with POL.
A higher concentration of POL was required to
achieve prolongation of most clotting tests when com-
pared to STS. POL never achieved the same degree of
prolongation when compared with STS.
In PRP, phospholipid sensitive XACT and SACT
times were shortened at low concentrations of sclero-
sant (less than 0.2% for STS and 0.4% for POL), indi-
cating the generation of procoagulant phospholipid.
Effect of time dependence
Both agents affected the XACT in a time dependant
fashion in both PRP and PPP (Fig. 3a and 3b). The pro-
longation of XACT tests by both sclerosants in PPP in-
creased with time. The shortening of XACT by both
sclerosants in PRP was also time dependent. There
was a general shift of the concentration curves to
the left, so that very low concentrations demonstrat-
ing no significant change in the clotting time, ex-
hibited shortening effects after 2.5 hours and low
concentrations showing shortening of XACT, demon-
strated prolongation after 2.5 hours of incubation. For
example, 0.15% STS demonstrated an XACT time of
44 seconds at time 0 but that changed to 13.5 seconds
after 2.5 hours. Conversely, when 0.3% STS was tested
after 2.5 hours at 20 C , the XACT prolonged from
22.4 seconds (time 0) to 73 seconds (time 2.5 h)
indicating further destruction of platelets and micro-
particles and an increase in anticoagulant activity
with increase in the exposure time. Similar results
were obtained for POL. Results are shown in Fig. 3a
and 3b.
Clotting factor assays
Certain clotting factor activities were reduced by STS,
with the largest reduction in activity on Factors V, VII
Eur J Vasc Endovasc Surg Vol 34, December 2007
734 K. Parsi et al.Fig. 1. The effect in PPP of STS (C) and POL (:) on various clotting tests (n[ 3). a) TT, b) PT, c) APTT (SynthaFax), d)
XACT, e) NAPTT, f) SACT. Error bars represent the Standard Error of the Mean.
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735Sclerosants and CoagulationFig. 2. Effect in PRP of STS (C) and POL (:) on various clotting tests (n¼ 3). a) TT, b) PT, c) APTT (Synthafax), d) XACT, e)
NAPTT, f) SACT. Error bars represent the Standard Error of the Mean.
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time dependent as clotting factor activity was mark-
edly reduced in samples incubated for 30 minutes
when compared with 5 minutes. Apparent activities
of factors VIII, IX, XI and XII were slightly increased
by POL at 5 and 30 minutes. Activities of factors V,
X, and VII were slightly reduced by POL at 5 and 30
minutes. The reduction in clotting factor activity after
30 minutes was much more pronounced with STS
when compared with POL.
Fig. 3. (a). Effect of sodium tetradecyl sulphate (STS) in nor-
mal platelet rich plasma on XACT test initially (:) and after
2.5 hours’ incubation (D). (b). Effect of Polidocanol (POL) in
platelet rich plasma on XACT test initially (C) and after 2.5
hours’ incubation (B).
Eur J Vasc Endovasc Surg Vol 34, December 2007To further investigate the changes in the activity of
clotting factors, dilution experiments were performed.
The tests were carried out on pooled normal plasma
(PNP) preincubated with 0.3% STS or with 0.3% of
POL for 5 minutes and 30 minutes at 20 C (Table 2).
Typical factor assay results for factor V are shown in
Fig. 4a. The calibration curve obtained by plotting
a clotting time (in this case PT) against concentration
of factor V provided by appropriate dilutions of
PNP mixed with factor V deficient plasma was used
as a reference. Samples simply deficient in factor V
usually yield long clotting times and lines parallel to
the reference line, thus allowing simple interpolation
to estimate factor V levels. However with sclerosants
present in test samples the lines were not parallel as
shown in Fig. 4b. In highly diluted samples, the resid-
ual sclerosant being also dilute had no effect on the
clotting tests. However, in the more concentrated
(less diluted, eg 1/5) samples, the residual sclerosant
exerted a prolonging effect on the clotting times.
These interfering effects were reduced as the sample
were diluted and thus more valid results were ob-
tained with more dilute samples.
It is clear that a true deficiency of factor V was in-
duced by STS after 30 minutes incubation because the
entire dilution line has moved to longer clotting times
as shown in Fig. 4b. 1/5 dilutions showed non specific
effects from higher levels of residual sclerosants. Thus
assay results shown in Table 2 were derived from the
linear portion of the graph, ie samples with 1/10 dilu-
tions and higher. POL increased the apparent activity
of intrinsic factors VIII, IX, XI and XII as it shortened
APTT.
Macroscopic effects on platelets
Sample turbidity was decreased upon incubation with
POL, indicating the lysis of platelets (Fig. 5). STS also
Table 2. Effect of Sclerosants on Clotting Factors. Factor assays
carried out on pooled normal plasma (PNP[ 100% activity all
factors initially) mixed with 0.3% of either Polidocanol (POL) or
sodium tetradecyl sulphate (STS) for 5 minutes or 30 minutes at
20C
FACTOR PNP with 0.3% POL PNP with 0.3% STS
T¼ 5 min T¼ 30 min T¼ 5 min T¼ 30 min
II 102% 97% 96% 92%
V 70 59 54 7
X 76 75 90 20
VII 82 79 72 5
VIII 117 106 97 61
IX 111 119 88 31
XI 152 126 90 42
XII 135 135 105 107
737Sclerosants and Coagulationreduced the turbidity of PRP at low concentrations
but then increased turbidity at higher concentrations.
This increased turbidity with STS concentrations
above 0.5% was apparent also in PPP (not shown).
The increase in sample turbidity was found to be
due to precipitation of a complex of unknown plasma
protein with or by STS. The material precipitated was
insoluble in plasma, water and even 5% sodium do-
decyl sulphate solution. Thus proteins contained
within could not be analysed by SDS PAGE. It was
sent to a facility for proteomic analysis where it was
subjected to amino acid analysis and tryptic digestion.
Mass spectrometric analysis using MALDI and
computer analysis of the main fragments showed
the main components to be apolipoprotein B and
fibrin(ogen) (results not shown). As trypsin was
Fig. 4. (a). Results of Factor Vassays based on the prothrom-
bin time (PT) test. Figure shows calibration curve of PT plot-
ted against factor V level in dilutions of pooled normal
plasma (-). The other curves show PT plotted against dilu-
tion of PNP mixed with either 0.3% STS (C) or 0.3% POL
(:) for 5 min. (b). Results as described for Fig 4a but with
samples aged at 20 C for 30 minutes.used for solubilisation, differentiation between fibrin
and fibrinogen could not be made.
Microparticle analysis
Increased microparticle counts were detected in PRP
samples for sclerosant concentrations greater than
Fig. 5. (a) Sodium tetradecyl sulphate (STS) in platelet rich
normal plasma (PRP). Showing absorbance at 415 nm due
to platelets in PRP as a function of STS concentration after
increasing time at 20 C (5 min ,, 10 min 6, 20 min C,
40 min A and 60 min :). (b) Polidocanol (POL) addition
to platelet rich plasma (PRP). Showing decrease in turbidity
(415 nm) due to platelet lysis as a function of POL concen-
tration after increasing time at 20 C. (5 min ,, 10 min 6,
20 min C, 40 min A and 60 min :). Error bars represent
the Standard Error of the Mean.
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ticle counts began to decrease and this corresponded
to similar decreases in procoagulant phospholipid ac-
tivity, as assessed by the XACT method (Fig. 2 d). Both
agents showed the same overlapping pattern for mi-
croparticles (Fig. 6), but their effects on clotting tests
and in particular XACT test were quite different at
high concentrations (Fig. 2). This is because STS at
higher concentrations prolongs the XACT test due to
its interference with the thrombin-fibrinogen interac-
tion whereas POL does not. Thus STS and POL form
microparticles similarly but STS has an additional in-
hibitory effect on XACT at concentrations above 0.3%.
Discussion
STS and POL are the two most commonly used sclero-
sants worldwide. The sclerosant concentration is cho-
sen based upon the vessel diameter as well as the
volume and speed of blood flow in the target vessel.
Higher concentrations are required to occlude large
vessels or to treat smaller vessels demonstrating
high flow rates.
Ultrasound guidance monitors the delivery of the
sclerosants into the target vessels. The movement of
the sclerosant can be traced from the superficial veins
(usual target vessels) to the deep veins via perforating
Fig. 6. Effect in PRP of STS (C) and POL (:) on mean mi-
croparticle counts (n[ 3). PRP was incubated with varying
concentrations (0e0.6%) STS or POL for 30 mins before mi-
croparticle quantitation. Error bars represent the Standard
Error of the Mean.
Eur J Vasc Endovasc Surg Vol 34, December 2007veins and junctions. Despite this, deep vein thrombo-
sis (DVT) remains a rare complication of UGS.23,24 An
interesting paradox appears with sporadic reports of
DVT following direct vision sclerotherapy of reticular
veins using low concentration agents.25
We investigated the thrombotic activity of both
sclerosants. At higher concentrations, both agents
demonstrated anticoagulant activity. STS demon-
strated more anticoagulant activity than POL on con-
ventional clotting tests. It prolonged all clotting tests
at concentrations higher than 0.3% and dissolved
and inactivated procoagulant phospholipids causing
lysis of procoagulant microparticles.
TT results were prolonged by increasing concen-
trations of STS, but not with POL. TT measurement
is dependant on thrombin and fibrinogen but not
on phospholipids. Being a potent anionic detergent,
STS affects proteins which can explain its prolonga-
tion of TT. Predictably, POL being a non-ionic deter-
gent did not affect the TT as it primarily targets
phospholipids.
POLhaspreviously been reported to activate contact
factors in vitro.10 In our study POL did not shorten the
NAPTT on either PPP or PRP and it seems unlikely to
be activating contact factors in vitro. It is possible that
denuded blood vessels may cause contact activation.
Both agents reduced sample turbidity indicating ly-
sis of platelets. STS, however, increased the sample
turbidity at concentrations above 0.5% due to forma-
tion of a precipitate of apolipoprotein B and fibrin
(ogen). We can only postulate that such deposits can
possibly occlude small vessels leading to arteriolar is-
chemia and possibly to skin necrosis associated with
sclerotherapy.
At low concentrations, both sclerosants demon-
strated some procoagulant activity in PRP. Both
agents shortened phospholipid dependent clotting
tests such as SACT and XACT at concentrations lower
than 0.2e0.3%. Slightly shortened SACTand XACTre-
sults in PPP suggest that STS may be mimicking pro-
coagulant phospholipid. We further explored this
procoagulant activity by investigating the formation
of platelet-derived microparticles. Microparticle
counts reflected the change in procoagulant activity,
with increasing microparticle counts occurring with
low doses of sclerosants, and a subsequent decrease
in microparticle formation at higher doses. To our
knowledge this is the first report of the formation of
microparticles by detergent sclerosants. Damage to
the platelet membrane by low-doses of sclerosants in-
duces platelet lysis and the subsequent release of mi-
croparticles, possessing procoagulant phospholipid
activity. At higher sclerosant concentrations, both
platelets and microparticles are destroyed, resulting
739Sclerosants and Coagulationin decreased procoagulant phospholipid. In this
study, the release of microparticles occurred at thera-
peutic concentrations of sclerosants and provides
a novel mechanism by which platelet-derived micro-
particle formation may be induced in vivo. Micropar-
ticles also possess angiogenic properties30,31 and may
play a role in pathogenesis of post-sclerotherapy tel-
angiectatic matting.
Sclerosants demonstrated interesting effects on the
clotting factors. STS was found to significantly destroy
mainly the clotting factors V, VII and Xwhen incubated
with pooled normal plasma at 0.3% for 30 minutes. At
lower concentrations (0.15e0.2%), the reduction in
clotting factor activity occurred immediately. This
immediate prolongation of the clotting tests cannot
be explained by an immediate destruction of clotting
factors but rather to a non-specific inhibitory effect,
probably on the procoagulant phospholipid necessary
for these tests to work. This inhibitory activity was
apparent in factor assays based on the PT, especially
with the 1/5 dilutions.
In contrast to STS, 0.3% POL in normal plasma in-
creased the apparent activity of intrinsic factors VIII,
IX, XI and XII as measured by APTT suggesting a pro-
coagulant activity. There are other agents reported to
have a similar effect on clotting tests.26e29 Lupus anti-
coagulants are typical agents which interfere with
clotting factor assays in a similar way. POL in general
demonstrates a procoagulant profile in concentration
range of 0.3e0.6%. The Australian Polidocanol Study
reported 3 cases of DVT when 0.5%e1% POL was
used to treat telangiectasias (spider veins). Interest-
ingly, the 3% concentration used to treat varicose
veins did not produce a DVT.25
Immediate walking after sclerotherapy has been
recommended in order to reduce the exposure of the
deep veins to the sclerosants. Time dependence exper-
iments were performed to investigate the relationship
between the exposure time and procoagulant activity
(Fig. 3a and 3b). Low concentration sclerosants (eg.
0.15% STS) with minimal effects on the clotting tests,
given the increase exposure time achieve procoagu-
lant activity by damaging the platelets and releasing
microparticles. Given the dilution effects and plasma
protein binding, a lower concentration of the sclero-
sants, as compared with what was initially injected,
may reach the deep venous system with potential pro-
coagulant activity. This may justify immediate walk-
ing after sclerotherapy to reduce the exposure of
deep veins to low concentration sclerosants.
In summary, we have demonstrated the effect of
the sclerosants on the coagulation mechanism to be
concentration and time dependant. At lower concen-
trations both STS and POL exhibit procoagulantactivity through stimulation of platelet lysis and the
release of procoagulant platelet-derived microparti-
cles. Also, low concentration POL increases the appar-
ent activity of most clotting factors. Procoagulant
activity increases with increased exposure time. At
higher concentrations procoagulant activity is lost,
possibly due to the additional lysis of the microparti-
cles and in the case of STS, destruction of certain
clotting factors. STS exhibits potent anticoagulant
properties at concentrations higher than 0.3% in vitro.
This may partly explain the low incidence of deep
vein thrombosis when these agents are used in high
concentrations clinically.
Both STS and POL are produced in liquid format
but most clinicians prefer to use them to treat varicose
veins in the foam format. Due to technical reasons, we
only investigated the liquid sclerosants in this study.
The effects of foam sclerosants on the coagulation sys-
tem and the clinical relevance of the present study
will be further investigated by the authors in in vivo
studies.
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